Establishing a new therapeutic modality doesn’t happen overnight. There are no silver bullets here: every new modality has its own specific strengths and limitations, all of which must be thoroughly explored and understood to identify its most effective “applicability space”.
Through years of careful and rigorous experimentation, Ribometrix has accumulated unique insights and proprietary capabilities to identify which RNA structures are most readily druggable. Such targeting “hot spots” can host highly potent and selective small molecule interactions capable of modulating the function of such RNAs in the production of encoded proteins. This crucial knowledge assures that ongoing Ribometrix efforts are focused on those therapeutic opportunities that offer the best chance of success.